Explore the vast range of titles available.

General comments In a recent study entitled “Synergistic Treatment of Sodium Propionate and Sishen Pill for Diarrhea Mice with Kidney-Yang Deficiency Syndrome” was published in Frontiers in Cellular and lnfection Microbiology”.Synergistic Treatment of Sodium Propionate and Sishen Pill for Diarrhea Mice with Kidney-Yang Deficiency Syndrome” (Guo et al., 2025) pioneers an integrative therapeutic strategy combining sodium propionate—a gut microbiota-modulating short-chain fatty acid—with Sishen Pill, a classic TCM formula, to address diarrhea in murine models of kidney-yang deficiency syndrome. [...]several mechanistic ambiguities warrant critical examination. [...]the pharmacokinetic interplay between SSP polyphenols and SP absorption necessitates investigation via Caco-2 transwell assays and hepatic microsomal stability testing (Zhang et al., 2015). [...]the neuroendocrine dimension of KYDS—particularly HPA axis modulation—remains unexplored; future research should assess corticosterone rhythms and adrenal glucocorticoid output in treated models. 1.

To learn more about gene editing and ALS, and to provide a comprehensive view of gene editing for further treatment of amyotrophic lateral sclerosis. We searched 1981 records from Web of Science core collection and Pubmed, Scopus, of which 1,292 records were obtained after exclusion. We then scientifically and metrologically analyzed these records for spatial and temporal distribution, author distribution, subject categories, subject distribution, references, and keywords using R, software CiteSpace and VOSviewer. Our analysis provides basic information about research in the field, suggests that the field has stabilized over the past decade, and identifies potential partners for interested researchers. Current research in this area is focused on inflammatory mechanisms, immune mechanisms, related diseases, and associated cytokines in ALS. RNA Editing, Antisense Bligonucleotide, and Glycine Receptor are cutting-edge research topics in this field, which is undergoing rapid development. We hope that this work will provide new ideas for advancing the scientific research and clinical application of ALS.

Background Canakinumab is a fully human monoclonal antibody that primarily targets interleukin-1β (IL-1β) and is primarily indicated for systemic juvenile idiopathic arthritis (sJIA). Since it is predominantly used in children aged 0–16 years, exploring its safety in real-world settings is of paramount importance. Methods This study evaluated the real-world safety of Canakinumab in clinical practice by analyzing adverse events (AEs) associated with the use of the drug in the 0–16 year age group with sJIA from 2014 to 2023, using data retrieved from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis of relevant AEs was performed via four methods: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the multi-item gamma Poisson shrinker (MGPS), and the Bayesian confidence propagation neural network (BCPNN). Additionally, the Weibull shape parameter (WSP) test distribution was employed to model the risk of AEs over time. Results A total of 439 adverse events (AEs) were included in this study. Positive signals were identified for several adverse reactions listed on the drug label, including inappropriate schedule of product administration, incorrect dose administered, rash, illness, gastroenteritis, thrombocytopenia, lymphadenopathy, leukopenia, transaminases increased, aspartate aminotransferase increased and alanine aminotransferase increased. Furthermore, the study identified potential adverse reactions not mentioned on the label, such as hemophagocytic lymphohistiocytosis, COVID-19, nasal congestion and increased serum ferritin. These findings underscore the importance of AE monitoring, particularly emphasizing the value of early detection. Conclusion This FAERS-based pharmacovigilance study provides preliminary safety data on the use of Canakinumab in children aged 0–16 years with sJIA, confirming several known adverse reactions and revealing additional potential risks. These findings offer clinicians valuable safety information for the use of Canakinumab in the treatment of sJIA.

This study aimed to explore the core factors influencing participation in the \"shared elderly care\" model among urban Chinese seniors and propose targeted solutions to address the challenges of an aging society. A mixed-methods study was conducted. A questionnaire survey was conducted among 533 seniors in Zhengzhou. Data on demographic characteristics, health literacy, and environmental factors were analyzed using four machine learning algorithms: logistic regression, random forest, K-nearest neighbor, and support vector machine. Approximately 3 years later, qualitative validation was conducted through six focus group interviews. Themes were extracted using Colaizzi phenomenological analysis, and the predictions were validated. Five hundred valid questionnaires were collected. The machine learning algorithm results showed that the random forest model had the best predictive performance (AUC = 0.652), revealing that e-health literacy and policy awareness were key drivers (jointly explaining 24.1% of the variance in participation intention), with age, environmental sensitivity, and social influence as significant cofactors. Qualitative analysis confirmed that technology usability and a sense of social belonging were core experiential elements of deep participation. Addressing the primary obstacles of digital literacy gaps and limited technological accessibility, we propose three countermeasures: increasing publicity and promotion of shared elderly care models; conducting community digital health literacy training; and increasing resource allocation to precisely match needs, thus providing an implementation path for building an inclusive shared elderly care ecosystem.

Hejia Wan,1 Yifan Li,2 Fei Xu3 1School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China; 2Joint Institute of Management and Science University at Henan University of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China; 3School of Information Technology, Henan University of Chinese Medicine, Zhengzhou, People’s Republic of ChinaCorrespondence: Hejia Wan, Email 2022140071@hactcm.edu.cn

Hejia Wan, Shuning Wang, Lanxia PanSchool of Nursing,Henan University of Chinese Medicine, Zhengzhou, People’s Republic of ChinaCorrespondence: Lanxia Pan, Email [email protected]View the original paper by Dr Zhou and colleagues

Pain is complex and subjective, causing physical and psychological damage. Western medical treatments are prone to dependence, gastrointestinal problems, and organ damage. Battlefield acupuncture (BFA) integrates traditional Chinese medicine with contemporary military medicine, achieving a rapid analgesic effect. In the domain of pain management, it is effective. Despite controversy, it is recommended as an analgesic for pain populations. The present study evaluated the clinical efficacy and safety of BFA, with a view to informing pain management strategies and validating its credibility. Databases including PubMed, Cochrane Library, Web of Science, and Embase were searched from 2015-2025. Randomized controlled studies(RCTs) on BFA for pain were included. Outcome measurements were pain scores and adverse event rates. Two authors independently assessed studies using the Cochrane risk of bias tool for randomized trials(RoB-1). Heterogeneity was addressed via narrative synthesis. Of 800 articles screened, 11 RCTs (n=1,232; BFA: 530 patients) matched criteria. BFA was compared with opioids, non-opioids, exercise or physical therapies for various types of pain. Four studies reported lower BFA pain scores, and four found no difference. No severe adverse event rates were noted, but mild reactions were recorded. RoB grades: two A, eight B, one C. Evidence supports the efficacy and safety of BFA for acute pain. The utilisation of BFA in the context of alleviating mild to moderate pain is recommended, particularly in conjunction with electroacupuncture therapies.However, limitations include small sample sizes, blinding issues, and inconsistent protocols. Research into specific pain types and long-term efficacy should be focused on. PROSPERO CRD420251011281.